Skip to main content
Infilbray™ (venglustat) logo
A young woman who is sitting and painting, overlayed with purple light
A young woman who is sitting and painting, overlayed with purple light

CareConnect™ Personalized Support Services

What you’ll learn on this page:

  • CareConnect provides information, education, and connections to the community for patients at all stages of their Gaucher disease type 3 journey
  • CareConnect also offers a variety of programs to help eligible patients access and afford treatment with Infilbray™ (venglustat)

Connected care throughout the journey

CareConnect is a free, voluntary, and confidential support program for eligible patients and families living with Gaucher disease type 3.

Connected Education: 

Comprehensive disease education from diagnosis and beyond for individuals, families, and communities.

Connected Team: 

Dedicated team who connects the dots between specialists, insurance, and appointments for a less fragmented care experience.

Connected Experience:

Programs designed to support your patients by connecting them with experts and the community to navigate life transitions and disease management.

Dynamic patient support professionals provide best-in-class support

Case Managers assist with reimbursement matters, provide financial assistance resources, and help patients navigate access hurdles throughout treatment.

Patient Education Liaisons leverage their clinical backgrounds to provide patients with disease and treatment education throughout their journey.

Rare Disease Products can be purchased through authorized distributors, specialty pharmacies, or directly through Sanofi. For more information, please contact Sanofi’s Rare Disease Product Services team at 1-800-745-4447, option 1, or email CO@Sanofi.com.

Enrolling in CareConnect can help patients start and stay on treatment with Infilbray

If your patient is already enrolled:

  • Connect with your patient's dedicated Case Manager for assistance during the treatment initiation process

If your patient is NOT enrolled:

Access resources to help navigate the insurance approval process

CareConnect can help you explore available financial support options

QuickStart Program

  • New, commercially insured patients prescribed Infilbray for the first time can receive a limited supply of product while prior authorizations and/or appeals are pending

Copay Program*

  • Helps eligible patients in the US who are prescribed certain Sanofi therapies pay for eligible out-of-pocket drug costs and specified infusion-related charges, including copays, coinsurance, and deductibles, up to the program maximum

Patient Assistance Program†

  • Established in the US to provide certain Sanofi therapies at no cost to eligible patients who do not have health insurance or cannot access an eligible product under the terms of their insurance plan. The program is considered a temporary solution until coverage can be secured

Patients must be enrolled in CareConnect to participate in these programs.

Connect with your patient's dedicated Case Manager to access the appropriate program(s).

If you don't have your patient's dedicated contact, call 1-800-745-4447, option 3 or email info@CareConnectPSS.com to reach a Case Manager.

For all programs, patients must reside in the US or a US territory where Infilbray is available. Patients must be treated by a healthcare professional residing in the US. Other eligibility restrictions apply.

*Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs. No claim for reimbursement of any out-of-pocket costs may be submitted to any third-party payer, whether public or private, including but not limited to patients’ insurance,
Flexible Spending Account (FSA), Health Savings Account (HSA), or any other type of medical savings account. This program is not valid where prohibited by law, taxed, or restricted. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided on the program may vary
depending on patients’ out-of-pocket costs. Patients will receive all program details upon registration. 
    
†The Patient Assistance Program is not available to those with commercial insurance whose plans work with a third-party Alternative Funding Program. Call CareConnect at 1-800-745-4447, option 3, for Patient Assistance Program terms and conditions.

Relevant pages to view:

Indication

INFILBRAY (venglustat) is indicated for the treatment of neurological manifestations of Type 3 Gaucher disease (GD3) in patients weighing at least 15 kg. 

Important Safety Information

Warnings and Precautions:
Suicidal Ideation and Behavior:

Suicidal ideation and behavior have been reported in patients with GD3 receiving INFILBRAY and in unapproved populations receiving another formulation of venglustat, both with and without a history of psychiatric disorders. Assess patients' underlying risk of psychiatric disorders prior to initiation and monitor for depressive symptoms or suicidal thoughts during treatment. Use caution when prescribing to patients with a history of psychiatric disorders. Inform patients or caregivers of the potential for behavioral and mood changes and to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, or other mood changes. Consider changing the therapeutic regimen, including possibly discontinuing INFILBRAY, if such events occur.

Lens Opacification in Pediatric Patients:

Lens opacification may occur in pediatric patients treated with INFILBRAY. In pediatric patients, perform ophthalmological assessment prior to initiation and annually during treatment. Advise pediatric patients and caregivers to report any visual disturbances during treatment.

Embryofetal Toxicity:

Based on animal studies, INFILBRAY may cause fetal harm when administered to a pregnant woman. Prior to initiation, verify pregnancy status in females of reproductive potential and advise them of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 11 days after the last dose.

Adverse Reactions:
The most common adverse reactions reported in ≥10% of INFILBRAY-treated GD3 patients aged ≥12 years were diarrhea, splenomegaly, nausea, depression, gastroenteritis, and vomiting.


Drug Interactions:
Strong CYP3A Inhibitors: Avoid concomitant use with INFILBRAY. Strong CYP3A inhibitors increase venglustat exposure, which may increase the risk of adverse reactions. If concomitant use is unavoidable, reduce INFILBRAY dosage.

Strong or Moderate CYP3A Inducers: Avoid concomitant use with INFILBRAY. Strong or moderate CYP3A inducers decrease venglustat exposure, which may result in decreased efficacy. If concomitant use is unavoidable, monitor for reduced effectiveness.

Please see Full Prescribing Information for INFILBRAY.

Indication

Important Safety Information

©2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2608192-v1.0-11/2026. Last updated: November 2026.